» Articles » PMID: 33474798

A Novel Equivalence Probability Weighted Power Prior for Using Historical Control Data in an Adaptive Clinical Trial Design: A Comparison to Standard Methods

Overview
Journal Pharm Stat
Publisher Wiley
Date 2021 Jan 21
PMID 33474798
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

A standard two-arm randomised controlled trial usually compares an intervention to a control treatment with equal numbers of patients randomised to each treatment arm and only data from within the current trial are used to assess the treatment effect. Historical data are used when designing new trials and have recently been considered for use in the analysis when the required number of patients under a standard trial design cannot be achieved. Incorporating historical control data could lead to more efficient trials, reducing the number of controls required in the current study when the historical and current control data agree. However, when the data are inconsistent, there is potential for biased treatment effect estimates, inflated type I error and reduced power. We introduce two novel approaches for binary data which discount historical data based on the agreement with the current trial controls, an equivalence approach and an approach based on tail area probabilities. An adaptive design is used where the allocation ratio is adapted at the interim analysis, randomising fewer patients to control when there is agreement. The historical data are down-weighted in the analysis using the power prior approach with a fixed power. We compare operating characteristics of the proposed design to historical data methods in the literature: the modified power prior; commensurate prior; and robust mixture prior. The equivalence probability weight approach is intuitive and the operating characteristics can be calculated exactly. Furthermore, the equivalence bounds can be chosen to control the maximum possible inflation in type I error.

Citing Articles

Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure.

Nielsen D, Hsu M, Zapata 3rd M, Ciavarra G, van Zyl L Sci Rep. 2025; 15(1):169.

PMID: 39747518 PMC: 11697272. DOI: 10.1038/s41598-024-84069-w.


Evaluation of the Fill-it-up-design to use historical control data in randomized clinical trials with two arm parallel group design.

Wied S, Posch M, Hilgers R BMC Med Res Methodol. 2024; 24(1):197.

PMID: 39251907 PMC: 11382532. DOI: 10.1186/s12874-024-02306-2.


On the use of non-concurrent controls in platform trials: a scoping review.

Bofill Roig M, Burgwinkel C, Garczarek U, Koenig F, Posch M, Nguyen Q Trials. 2023; 24(1):408.

PMID: 37322532 PMC: 10268466. DOI: 10.1186/s13063-023-07398-7.


Being Bayesian in the 2020s: opportunities and challenges in the practice of modern applied Bayesian statistics.

Bon J, Bretherton A, Buchhorn K, Cramb S, Drovandi C, Hassan C Philos Trans A Math Phys Eng Sci. 2023; 381(2247):20220156.

PMID: 36970822 PMC: 10041356. DOI: 10.1098/rsta.2022.0156.


A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.

Zhang W, Pan Z, Yuan Y J Biopharm Stat. 2022; 32(3):359-372.

PMID: 35679137 PMC: 9378566. DOI: 10.1080/10543406.2022.2080700.


References
1.
Bennett M, White S, Best N, Mander A . A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods. Pharm Stat. 2021; 20(3):462-484. PMC: 8611797. DOI: 10.1002/pst.2088. View

2.
Morita S, Thall P, Muller P . Determining the effective sample size of a parametric prior. Biometrics. 2007; 64(2):595-602. PMC: 3081791. DOI: 10.1111/j.1541-0420.2007.00888.x. View

3.
Ibrahim J, Chen M, Gwon Y, Chen F . The power prior: theory and applications. Stat Med. 2015; 34(28):3724-49. PMC: 4626399. DOI: 10.1002/sim.6728. View

4.
Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N . Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2013; 13(1):41-54. PMC: 3951812. DOI: 10.1002/pst.1589. View

5.
Gravestock I, Held L . Adaptive power priors with empirical Bayes for clinical trials. Pharm Stat. 2017; 16(5):349-360. DOI: 10.1002/pst.1814. View